A Novel Therapeutic Approach in the Treatment of Pulmonary Arterial Hypertension: Allium ursinum Liophylisate Alleviates Symptoms Comparably to Sildenafil

被引:11
|
作者
Bombicz, Mariann [1 ]
Priksz, Daniel [1 ]
Varga, Balazs [1 ]
Kurucz, Andrea [1 ]
Kertesz, Attila [2 ]
Takacs, Akos [1 ]
Posa, Aniko [3 ]
Kiss, Rita [1 ]
Szilvassy, Zoltan [1 ]
Juhasz, Bela [1 ]
机构
[1] Univ Debrecen, Dept Pharmacol & Pharmacotherapy, Fac Med, H-4032 Debrecen, Hungary
[2] Univ Debrecen, Dept Cardiol, Fac Med, H-4032 Debrecen, Hungary
[3] Univ Szeged, Fac Sci & Informat, Dept Physiol Anat & Neurosci, H-6726 Szeged, Hungary
关键词
Allium ursinum; pulmonary arterial hypertension; phosphodiesterase; sildenafil; monocrotaline; CGMP PHOSPHODIESTERASE; MODEL; INHIBITION; RATS; METABOLISM; EXPRESSION; BIOMARKERS; MORTALITY; PRESSURE; ISCHEMIA;
D O I
10.3390/ijms18071436
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Right-sided heart failure-often caused by elevated pulmonary arterial pressure-is a chronic and progressive condition with particularly high mortality rates. Recent studies and our current findings suggest that components of Wild garlic (Allium ursinum, AU) may play a role in reducing blood pressure, inhibiting angiotensin-converting enzyme (ACE), as well as improving right ventricle function in rabbit models with heart failure. We hypothesize that AU may mitigate cardiovascular damage caused by pulmonary arterial hypertension (PAH) and has value in the supplementary treatment of the complications of the disease. In this present investigation, PAH was induced by a single dose of monocrotaline (MCT) injection in Sprague-Dawley rats, and animals were divided into 4 treatment groups as follows: I. healthy control animals (Control group); II. pulmonary hypertensive rats (PAH group); III. pulmonary hypertensive rats + daily sildenafil treatment (Sildenafil group); and IV. pulmonary hypertensive rats + Wild garlic liophylisate-enriched chow (WGLL group), for 8 weeks. Echocardiographic measurements were obtained on the 0 and 8 weeks with fundamental and Doppler imaging. Isolated working heart method was used to determinate cardiac functions ex vivo after thoracotomy on the 8th week. Histological analyses were carried out on excised lung samples, and Western blot technique was used to determine Phosphodiesterase type 5 enzyme (PDE5) expression in both myocardial and pulmonary tissues. Our data demonstrate that right ventricle function measured by echocardiography was deteriorated in PAH animals compared to controls, which was counteracted by AU treatment. Isolated working heart measurements showed elevated aortic flow in WGLL group compared to PAH animals. Histological analysis revealed dramatic increase in medial wall thickness of pulmonary arteries harvested from PAH animals, but arteries of animals in sildenafil-and WGLL-treated groups showed physiological status. Our results suggest that bioactive compounds in Allium ursinum could have beneficial effects in pulmonary hypertension.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: A systematic review
    Wang, Rong-chun
    Jiang, Fa-ming
    Zheng, Qiao-ling
    Li, Chun-tao
    Peng, Xia-ying
    He, Chen-yun
    Luo, Jian
    Liang, Zong-an
    RESPIRATORY MEDICINE, 2014, 108 (03) : 531 - 537
  • [22] Sildenafil and tadalafil, a new option in the treatment of patients with pulmonary arterial hypertension
    Konorza, T.
    Haude, M.
    Kaelsch, H.
    Neudorf, U.
    Katz, M.
    Neumann, T.
    Erbel, R.
    EUROPEAN HEART JOURNAL, 2005, 26 : 78 - 78
  • [23] Bosentan combined with sildenafil in the treatment of COPD patients with pulmonary arterial hypertension
    Li, Ying
    Wang, Yao
    Liu, Shaohua
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (10): : 11522 - 11530
  • [24] Treatment of pulmonary arterial hypertension with sildenafil: From pathophysiology to clinical evidence
    Raja, Shahzad G.
    Danton, Mark D.
    MacArthur, Kenneth J.
    Pollock, James C.
    JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2006, 20 (05) : 722 - 735
  • [25] Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension
    Grobs, Yann
    Awada, Charifa
    Lemay, Sarah-Eve
    Romanet, Charlotte
    Bourgeois, Alice
    Toro, Victoria
    Nadeau, Valerie
    Shimauchi, Kana
    Orcholski, Mark
    Breuils-Bonnet, Sandra
    Tremblay, Eve
    Provencher, Steeve
    Paulin, Roxane
    Boucherat, Olivier
    Bonnet, Sebastien
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 15
  • [26] Identification of Novel Therapeutic Targets for Pulmonary Arterial Hypertension
    Satoh, Kimio
    Kikuchi, Nobuhiro
    Satoh, Taijyu
    Kurosawa, Ryo
    Sunamura, Shinichiro
    Siddique, Mohammad Abdul Hai
    Omura, Junichi
    Yaoita, Nobuhiro
    Shimokawa, Hiroaki
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (12)
  • [27] Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension
    Jun-Dae Kim
    Aram Lee
    Jihea Choi
    Youngsook Park
    Hyesoo Kang
    Woochul Chang
    Myeong-Sok Lee
    Jongmin Kim
    Experimental & Molecular Medicine, 2015, 47 : e175 - e175
  • [28] Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension
    Kim, Jun-Dae
    Lee, Aram
    Choi, Jihea
    Park, Youngsook
    Kang, Hyesoo
    Chang, Woochul
    Lee, Myeong-Sok
    Kim, Jongmin
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2015, 47 : e175 - e175
  • [29] New approach of using sildenafil in the treatment of scleroderma pulmonary hypertension
    Yatsyshyn, R.
    Neyko, Y.
    Yatsyshyn, N.
    JOURNAL OF HYPERTENSION, 2006, 24 : S17 - S17
  • [30] Comparison of the Therapeutic and Side Effects of Tadalafil and Sildenafil in Children and Adolescents with Pulmonary Arterial Hypertension
    Mohammad Reza Sabri
    Elham Beheshtian
    Pediatric Cardiology, 2014, 35 : 699 - 704